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Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5-year survival of approximately 20%. The disease primarily
occurs in elderly patients. IPF is a highly heterogeneous disorder with a clinical course that varies from prolonged periods of
stability to episodes of rapid deterioration. In the last decade, improved understanding of disease mechanisms along with a more
precise disease definition has allowed the design and completion of a number of high-quality clinical trials. Yet, until recently,
IPF was essentially an untreatable disease. Finally, pirfenidone and nintedanib, two compounds with antifibrotic properties, have
consistently proven effective in reducing functional decline and disease progression in IPF.This is amajor breakthrough for patients
and physicians alike, but there is still a long way to go. In fact, neither pirfenidone nor nintedanib is a cure for IPF, and most
patients continue to progress despite treatment. As such, comprehensive care of patients with IPF, including management of
comorbidities/complications and physical debility and timely referral for palliative care or, in a small number of highly selected
patients, lung transplantation, remains essential. Several agents with high potential are currently being tested and many more are
ready to be evaluated in clinical trials.
1. Disease Overview
Idiopathic pulmonary fibrosis (IPF), the most common of
the idiopathic interstitial pneumonias (IIPs) and one of
the most prevalent interstitial lung diseases (ILDs), is a
chronic, progressive, and almost invariably fatal disorder
characterised by scarring of the lung and progressive loss
of function [1, 2]. The disease, which is limited to the lungs
and occurs primarily in older adults, is associated with
a radiological and/or histopathologic pattern of usual inter-
stitial pneumonia (UIP) [1], which, however, is not unique to
IPF, but can be found in a number of conditions, including
connective tissue diseases (CTDs), chronic hypersensitivity
pneumonitis (HP), and asbestosis. Accordingly, the diagnosis
of IPF requires the exclusion of all known causes of fibrotic
interstitial pneumonia and the presence of an idiopathic
UIP pattern [1]. IPF is an age-related condition; indeed, the
disease is unlikely to occur in individuals younger than 50
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but is present in approximately 0.2% of those older than
75 [3, 4]. The incidence of IPF, estimated at 3–9 cases per
100,000 per year in Europe and North America, is increasing
worldwide [5], and IPF is also likely to account for much
of the increased ILD-related mortality reported worldwide
between 1990 and 2013 [6]. Although the nature of the stimuli
that trigger the fibrotic process in IPF is still unknown,
several factors have been associated with an increased risk of
developing the disease, including cigarette smoking, environ-
mental/occupational pollutants, microbial agents, chronic
microaspiration secondary to gastroesophageal reflux, and
genetic abnormalities [7–9]. Despite its inexorably progres-
sive nature with a 5-year survival of approximately 20% in
historical cohorts [10–13], IPF is characterized by a highly
variable clinical course (e.g., periods of relative stability may
be punctuated by episodes of acute worsening often resulting
in respiratory failure and death), which makes the natural
history of the disease largely unpredictable in individual
patients [14].
The understanding of IPF pathobiology has substantially
improved over time, and this has shifted the approach
to treatment. Based on the traditional (and erroneous)
hypothesis that inflammation preceded fibrosis in IPF, the
2000 statement recommended corticosteroids in addition to
cytotoxic agents (either azathioprine or cyclophosphamide)
as the “standard treatment,” although limited and low-quality
data supported this recommendation [15]. Conversely, cur-
rent concepts suggest that on-going microinjury to alveolar
epithelial cells induces a fibrotic environment and that growth
factors secreted by the injured epithelial cells promote fibrob-
last recruitment, proliferation, and differentiation to invasive
myofibroblasts [16]. In turn, actively proliferating fibroblasts
and myofibroblasts organize into fibroblastic foci and are
responsible for the excessive collagen production that results
in scarring of the lung and architectural distortion [16, 17].
More recently, clinical trials have therefore shifted their focus
from anti-inflammatory and immunosuppressant drugs to
newer molecules with antifibrotic properties. Nevertheless,
most of these studies have been negative, probably due to
the multitude of mediators, growth factors, and signalling
pathways involved in the fibrotic process of IPF. Accordingly,
no pharmacological treatment was recommended by the 2011
guidelines; the only care options recommended were pallia-
tion and, in highly selected patients, lung transplantation [1].
Since the publication of the 2011 guideline, two
antifibrotic compounds, namely, pirfenidone and nintedanib,
have proven effective in reducing functional decline and
disease progression in IPF [18–20], whereas warfarin
and the three-drug regimen prednisone/azathioprine/N-
acetylcysteine, which in the 2011 document had been given
a weak recommendation against use, have subsequently
been shown to be harmful in patients with IPF [21, 22]. An
update of the 2011 Clinical Practice Guideline has therefore
been recently published [23]. In this paper, we summarize
the most recent advances in pharmacological treatment of
IPF and discuss challenges and future perspectives in the
management of this devastating disease.
2. The Updated 2011 Clinical
Practice Guideline
The current guideline on management of IPF is evidence-
based and includes quality and grading of the evidence.
For any given question, the panel of experts graded the
quality of the evidence available (e.g., high, moderate, low,
or very low, with the study designs of the highest quality of
evidence being randomized control trials (RCTs) and lowest
case reports and case series) and made a recommendation
for or against a given intervention. Recommendations were
decided on the basis of majority vote and were either “strong”
or “weak/conditional” [1, 23]. However, while in the 2011
guideline both conflicted and nonconflicted members were
allowed to participate without restrictions to all the key
steps of the recommendation formulating process, in the
2015 update only committee members without conflicts of
interest had the opportunity to vote on the recommendations
[23]. Notably, the exclusion of conflicted members from
voting on the recommendations, which was dictated by the
need to minimize potential bias, has probably resulted in
the paradox of pirfenidone, nintedanib, and antiacid therapy
which have being given the same recommendation (e.g.,
conditional/weak recommendation for use) despite differ-
ent levels of evidence (discussed later) [23]. No treatment
received a “strong yes” recommendation. In other words, no
treatment is strongly recommended by current guideline for
patientswith IPF.On the other hand, several pharmacological
treatments received a strong recommendation against use,
mostly due clear evidence of inefficacy. Table 1 summarizes
the key recommendations on pharmacological treatment of
IPF according to current guideline.
In the following section, only interventions that received
a conditional recommendation for use or a conditional recom-
mendation against use are reviewed (Table 2).
2.1. Pirfenidone. Pirfenidone is an orally available, synthetic
pyridone compound. Although its mechanism of action is
not fully understood, in vitro studies and animal mod-
els of pulmonary fibrosis suggest that pirfenidone exerts
antifibrotic, anti-inflammatory, and antioxidant properties
through downregulation of key profibrotic growth factors,
including transforming growth factor- (TGF-) 𝛽; inhibition
of cytokines and inflammatory cells; and scavenge of reactive
oxygen species (ROS), respectively [24, 25]. The efficacy
of pirfenidone in patients with IPF has been evaluated in
four randomized, double-blind, placebo-controlled, phase
3 clinical trials, one conducted in Japan [26] and three
multinational [18, 27]. The CAPACITY (Clinical Studies
Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis:
Research of Efficacy and SafetyOutcomes) programconsisted
of two almost identical studies (PIPF-004 and PIPF-006) and
enrolled patients aged 40–80 years with mild-to-moderate
functional impairment (forced vital capacity (FVC) > 50%
predicted and diffusion capacity of the lung for carbon
monoxide (DLCO) > 35% predicted). In study 004, 435
patients were assigned in a 2 : 1 : 2 dosing ratio to pirfenidone
2403mg/day, pirfenidone 1197mg/day, or placebo, whereas
study 006 enrolled 344 patients who were assigned in a 1 : 1
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Table 1: Key recommendations on pharmacological treatment of IPF according to current guideline.
2015 guideline 2011 guideline
Therapeutic agent
Pirfenidone Conditional recommendation for use∗ Weak recommendation against use
Nintedanib Conditional recommendation for use Not addressed
Antiacid therapy Conditional recommendation for use Weak recommendation for use
Phosphodiesterase-5 inhibitor
(sildenafil) Conditional recommendation against use Not addressed
Dual endothelin receptor antagonists
(bosentan, macitentan) Conditional recommendation against use Strong recommendation against use
N-acetylcysteine (NAC) Conditional recommendation against use Weak recommendation against use
Azathioprine + corticosteroids + NAC Strong recommendation against use Weak recommendation against use
Warfarin Strong recommendation against use Weak recommendation against use
Imatinib Strong recommendation against use Not addressed
Selective endothelin receptor antagonist
(ambrisentan) Strong recommendation against use Not addressed
∗Conditional recommendations are synonymous with weak recommendations.
Table 2: Interpretation of strong and conditional recommendations for stakeholders (patients, clinicians, and health care policy makers)∗.
Implications for Strong recommendation Conditional recommendation
Patients
Most individuals in this situation would
want the recommended course of action,
and only a small proportion would not.
The majority of individuals in this
situation would want the suggested
course of action, but many would not.
Clinicians
Most individuals should receive the
intervention. Adherence to this
recommendation according to the
guideline could be used as a quality
criterion or performance indicator.
Formal decision aids are not likely to be
needed to help individuals make
decisions consistent with their values and
preferences.
Recognize that different choices will be
appropriate for individual patients and
that you must help each patient arrive at a
management decision consistent with his
or her values and preferences. Decision
aids may be useful in helping individuals
to make decisions consistent with their
values and preferences.
Policy makers The recommendation can be adopted aspolicy in most situations.
Policy making will require substantial
debate and involvement of various
stakeholders.
∗Reproduced from [23].
ratio to pirfenidone 2403mg/day or placebo. The primary
endpoint of change in percentage predicted FVC from base-
line to week 72 was met in study 004 (e.g., mean FVC change
at week 72 was −8.0% in the pirfenidone 2403mg/day group
and −12.4% in the placebo group; 𝑝 = 0.001), whereas no
significant difference was observed between pirfenidone and
placebo in study 006. The CAPACITY trials provided mixed
results also for the secondary endpoints. Indeed, pirfenidone
significantly reduced the proportion of patients with an FVC
decline ≥ 10% and significantly prolonged progression-free
survival (PFS) (defined as time to confirmed ≥ 10% decline
in percentage predicted FVC, ≥15% decline in percentage
predicted DLCO or death) compared with placebo in study
004, but not in study 006. Conversely, pirfenidone signifi-
cantly reduced the decline in 6-minute walk test (6MWT)
distance compared with placebo in study 006, but not in
study 004. A Cochrane systematic review and meta-analysis
showed that pirfenidone significantly reduced the rate of
functional decline and disease progression (defined as time
to confirmed ≥10% decline in percentage predicted FVC/vital
capacity (VC) or death) compared with placebo [28].
In 2011 pirfenidone, which had already been approved
in Japan in 2008, was approved in Europe, whereas the US
Food and Drug Administration (FDA) denied approval and
requested an additional phase 3 study to provide supportive
evidence of efficacy. In ASCEND (Assessment of Pirfenidone
to Confirm Efficacy and Safety in Idiopathic Pulmonary
Fibrosis), 555 IPF patients were randomized 1 : 1 to pir-
fenidone 2403mg/day (𝑛 = 278) or placebo (𝑛 = 277) [18].
The studymet its primary outcome of change frombaseline to
week 52 in the percentage of predicted FVC (−164mL in the
pirfenidone arm versus −280mL in the placebo arm; absolute
difference 116mg, relative difference 41.5%; 𝑝 < 0.0001).
In addition, pirfenidone reduced by 47.9% the proportion
of patients with a decline of ≥10% in percentage predicted
FVC or who died and increased the proportion of patients
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who had no decline in percentage predicted FVC compared
with placebo (16.5% versus 31.8%, 𝑝 < 0.001, and 22.7%
versus 9.7%, 𝑝 < 0.001, resp.). Additional beneficial effects of
pirfenidone included a reduction in the decline of the 6MWT
distance (𝑝 = 0.036) and improved PFS (defined as the time
to the first occurrence of any one of the following: a confirmed
decrease of 10% or more in the predicted FVC, a confirmed
decrease of 50 meters or more in the 6MWT distance, or
death). Moreover, a prespecified pooled analysis including
also data from the two CAPACITY studies showed that pir-
fenidone compared with placebo significantly reduced both
all-cause mortality (3.5% versus 6.7%, resp.; 𝑝 = 0.01, HR:
0.52) and IPF-related mortality (1.1% versus 3.5%, resp.; 𝑝 =
0.006, HR: 0.32) at 52 weeks. Commonly reported treatment-
related adverse events included nausea, dyspepsia, dizziness,
vomiting, rash, photosensitivity reaction, anorexia, insomnia,
and abdominal distension, which however were mild-to-
moderate in severity and reversible and without clinically
significant sequelae. Recommendations on optimal manage-
ment of pirfenidone-related adverse events based on existing
guidelines and expert opinion have recently been published
[29]. The US FDA approved pirfenidone for the treatment of
IPF in October 2014. The 2015 guideline gives a conditional
recommendation for use of pirfenidone in patients with IPF
(e.g., “this recommendation puts a high value on the potential
benefit of pirfenidone on patient-important outcomes such as
disease progression as measured by rate of FVC decline and
mortality and a lower value on potentially significant adverse
effects and the cost of treatment”) [23].
2.2. Nintedanib. Nintedanib, an orally administered inhibitor
of multiple tyrosine kinases originally developed as an
anticancer drug, is a small molecule that targets vascular
endothelial growth factor receptors (VEGFR) 1–3, fibroblast
growth factor receptors (FGFR) 1–3, and platelet-derived
growth factor receptors (PDGFR) 𝛼 and 𝛽 [30]. VEGF,
FGF, and PDGF mediate a number of processes including
fibrogenesis and angiogenesis and have been implicated in
the pathogenesis of IPF [31]. The efficacy of nintedanib in
patients with IPF has been evaluated in two identical, ran-
domized, double-blind, placebo-controlled, multinational,
52-week duration, phase 3 trials (INPULSIS-1 and INPULSIS-
2) [19]. A total of 1,066 patients were randomly assigned in a
3 : 2 ratio to receive nintedanib 150mg twice daily (𝑛 = 309
in INPULSIS-1 and 𝑛 = 329 in INPULSIS-2) or placebo
(𝑛 = 204 in INPULSIS-1 and 𝑛 = 219 in INPULSIS-2).
Inclusion criteria included age ≥ 40 years, diagnosis of IPF
made within the previous 5 years, FVC of ≥50% of pre-
dicted value, DLCO of 30–79% of predicted value, and chest
high-resolution computed tomography (HRCT) performed
within the previous 12 months. Notably, in the absence of
a confirmatory surgical lung biopsy, the INPULSIS trials
allowed the enrolment of patients with a radiological pattern
of possible UIP [32]. In both trials nintedanib significantly
reduced the rate of decline in FVC over the study period
(the primary end point). In fact, the annual rate of decline
in FVC was −114.7mL in the nintedanib arm and −239.9mL
in the placebo arm in INPULSIS-1 (difference: 125.3mL;
𝑝 < 0.001) and −113.6mL and −207.3mL in INPULSIS-2
(difference: 93.7mL; 𝑝 < 0.001), respectively. Prespecified
sensitivity analyses, in particular the multiple imputation
analyses of missing data, confirmed that the results of the
primary analysis were robust [19]. In addition, in both trials
patients in the nintedanib arm were significantly more likely
than patients in the placebo arm to be functionally stable
at week 52 (e.g., to have no absolute decline in percent
predicted FVC > 5%; 52.8% versus 38.2%, 𝑝 = 0.001
in INPULSIS-1, and 53.2% versus 39.3%, 𝑝 = 0.001 in
INPULSIS-2, resp.). As for the key secondary end points, the
two trials providedmixed results in terms of both St. George’s
Respiratory Questionnaire (SGRQ), which was significantly
improved in INPULSIS-2 (𝑝 = 0.02) but not in INPULSIS-
1 (𝑝 = 0.97), and time to first acute exacerbation (AE),
which was statistically significant in INPULSIS-2 (𝑝 = 0.005)
but not in INPULSIS-1 (𝑝 = 0.67). However, based on
the results of a prespecified sensitivity analysis of pooled
data from INPULSIS-1 and INPULSIS-2, the time to first
adjudicated AE (either “confirmed” or “suspected” by an
expert adjudication panel) was significantly increased in
the nintedanib arm compared to placebo (𝑝 = 0.001).
Conversely, in a prespecified pooled analysis, the adjusted
mean change from baseline in the SGRQ total score did
not differ significantly between the nintedanib and placebo
groups [19]. In addition, in a prespecified pooled analysis,
a nonstatistically significant trend favouring nintedanib was
observed in all-cause mortality (5.5% in the nintedanib
arm versus 7.8% in the placebo arm, resp.; 𝑝 = 0.14,
HR: 0.70) or death from a respiratory cause (3.8% in the
nintedanib arm versus 5.0% in the placebo arm, resp.; 𝑝 =
0.34, HR 0.74). Overall, nintedanib showed an acceptable
safety and tolerability profile as shown by the comparable
incidences of adverse events across all groups [19]. The most
common drug-related side effects were diarrhea, nausea,
and vomiting. Among nintedanib and placebo recipients,
diarrhea was reported by 61.5% and 18.6% of patients in
INPULSIS-1 and 63.2% and 18.3% of patients in INPULSIS-
2, respectively. However, over 90% of cases of diarrhea were
mild-to-moderate. Nintedanib has recently been approved
both in USA and Europe for the treatment of IPF.
The 2015 guideline gives a conditional recommendation
for use of nintedanib in patients with IPF (e.g., “this rec-
ommendation puts a high value on the potential benefit of
nintedanib on patient-important outcomes such as disease
progression asmeasured by rate of FVCdecline andmortality
and a lower value on potentially significant adverse effects
and the expected cost of treatment”) [23].
2.3. Antiacid Therapy. Abnormal gastroesophageal reflux
(GER), including clinically silent GER, is highly prevalent in
patients with IPF and chronic microaspiration secondary to
GER is considered a risk factor for the development or wors-
ening of the disease [33]. In an uncontrolled retrospective
study of 204 IPF patients, antiacid treatment was associated
with reduced radiological fibrosis and longer survival time
[34]. In a more recent analysis of patients assigned to
placebo arms in three IPFnet-sponsored RCTs of different
pharmacological interventions (𝑛 = 242), patients taking
antiacid treatment at baseline (either proton-pump inhibitors
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blockers) had a smaller decrease in FVC at 30 weeks
compared with those not taking antiacid treatment (𝑝 =
0.05) after adjusting for sex, baseline percentage predicted
FVC, and baseline percentage predicted DLCO [35]. This
study showed no benefit of antiacid therapy on all-cause
mortality or all-cause hospitalization. Despite the lack of data
from prospective RCTs, the 2015 guidelines give a conditional
recommendation for use of antiacid therapy in patients with
IPF (e.g., this recommendation places a higher value on
possible improved lung function and survival and the low
cost of therapy and a lower value on the potential increased
risk for pneumonia) [23]. However, the panel acknowledged
the need for further research focusing on efficacy (e.g., RCTs
of antiacid therapy versus placebo) and long-term safety
of antiacid therapy as well as interactions with other IPF
medications.
2.4. Sildenafil. Sildenafil, an oral phosphodiesterase-5
inhibitor that stabilizes the second messenger of nitric
oxide (e.g., cyclic guanosine monophosphate) leading
to pulmonary vasodilatation, is approved for treatment
of pulmonary arterial hypertension (PAH) both as
monotherapy and in combination with other drugs [36].
Following promising results from a small open-label study
[37], the STEP-IPF (Sildenafil Trial of Exercise Performance
in Idiopathic Pulmonary Fibrosis) trial enrolled 180 patients
with advanced IPF (DLCO < 35% predicted) who were
randomized to either sildenafil (20mg three times daily) or
placebo for 12 weeks, with a subsequent 12-week open-label
phase during which all patients received the active drug [38].
The study did not meet its primary outcome, which was
the proportion of patients whose 6MWD improved by ≥20
meters. However, significant differences favoring sildenafil
were observed in some secondary outcomes (e.g., arterial
oxygen saturation, DLCO, degree of dyspnea, and quality
of life). In addition, a predefined subgroup analysis of 119
patients with available echocardiogram data showed that in
patients with echocardiographic evidence of right ventricular
systolic dysfunction sildenafil treatment was associated with
a significant improvement in the primary outcome of 6MWD
[39]. The recommendation on sildenafil use in patients with
IPF given by the recent guideline (e.g., conditional recom-
mendation against use) does not apply to patients receiving
phosphodiesterase inhibitors for approved indications such
as PAH or other forms of right ventricular dysfunction [23].
The guideline makes no specific recommendation for the
subset of patients with IPF and documented PH. Conversely,
the recent guidelines on PAH do not recommend the use
of sildenafil for treatment of IPF-associated pulmonary
hypertension (PH) and suggest to refer patients with
IPF-associated PH to highly specialized centers [23, 36].
2.5. Dual Endothelin Receptor Antagonists. The effect of
bosentan and macitentan, two dual endothelin receptor
antagonists (ERAs), in patients with IPF has been examined
in two RCTs and one RCT, respectively. In the BUILD-1
(BosentanUse in Interstitial LungDisease) study, 158 patients
were randomly assigned to receive either oral bosentan (𝑛 =
74) or placebo (𝑛 = 84) and followed up for 12 months [40].
While the study failed to meet its primary efficacy endpoint
(change in 6MWD by month 12), a treatment effect favoring
bosentan (e.g., delayed time to death or disease progression
and improvement in quality of life) was observed in a subset
of patients diagnosed by surgical lung biopsy. However,
the follow-up study (BUILD-3), which specifically enrolled
patients diagnosed histologically (𝑛 = 616), did not show an
effect of bosentan on time to disease worsening (defined by a
decline≥10% in FVC and≥15% inDLCO or an acute exacerba-
tion of IPF at month 12) or death, the primary endpoint [41].
The efficacy and safety of macitentan in IPF patients
have been evaluated in a prospective, randomized, double-
blind, multicentre, parallel-group, placebo-controlled, phase
2 proof-of-concept study (Macitentan Use in an Idiopathic
Pulmonary Fibrosis Clinical (MUSIC) trial) [42]. Of the 178
randomized patients, 119 were allocated to macitentan and
59 to placebo. The study did not meet its primary endpoint
(change from baseline up to month 12 in FVC). Similarly, no
differenceswere observed between treatment groups in any of
the secondary or exploratorymeasures, including time to IPF
worsening or death. Given the relatively similar mechanism
of action between these two compounds and the consistent
results, these three studies were pooled for analysis [23].
While no effect between groups was observed in FVC change
or mortality, the composite outcome of death or disease
progression appeared improved (relative risk: 0.85). The rec-
ommendation on bosentan and macitentan use in IPF made
by the recent guideline (e.g., conditional recommendation
against use) applies to the whole population of patients and
there is no specific recommendation for patients with IPF and
documented PH. Conversely, the recent guidelines on PAH
do not recommend the use of ERAs for treatment of IPF-
associated PH and strongly encourage to refer these patients
to highly specialized centers for IPF and PH [23, 36].
2.6. N-Acetylcysteine. N-acetylcysteine (NAC), a precursor
of the endogenous antioxidant glutathione (GSH), has been
used in IPF based on the assumption that an oxidant-
antioxidant imbalance plays a role in the pathogenesis of the
disease [43]. To date, three RCTs of NACmonotherapy in IPF
have been performed. In a small pilot study, Tomioka and col-
leagues randomized 30 patients with IPF to either aerosolized
NAC or bromhexine hydrochloride for 12 months [44]. They
observed that NAC treatment significantly reduced extent
of ground glass on HRCT and KL-6 levels. In a subsequent
multicenter, prospective study, 76 Japanese patients were
randomly assigned to receive either inhaled NAC or no
treatment for 48 weeks [45]. The study did not meet the
primary endpoint of change from baseline in FVC during the
study period, although NAC treatment was associated with
stability in FVC in a subset of patients with early disease (e.g.,
FVC < 95% of predicted and DLCO < 55% of predicted).
The third study was actually part of the IPFnet-sponsored
PANTHER (Prednisone, Azathioprine, andN-acetylcysteine:
A Study That Evaluates Response in IPF) trial, which had
been originally designed to compare three therapeutic inter-
ventions, combination prednisone, azathioprine, and high-
dose NAC (600mg three times daily), NAC alone, or placebo
[21]. However, following a prespecified efficacy and safety
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interim analysis planned at approximately 50% of data col-
lection, the combination therapy arm was terminated due to
major safety concern, and the study continued as a two-arm
study only (NAC monotherapy versus placebo). Compared
with placebo, NAC offered no significant benefit in terms
of preservation of FVC in patients with IPF [46]. Similarly,
no significant between-group differences were observed in
the rates of death or acute exacerbations. A pooled analysis
of these three studies did not reveal significant benefit of
NAC monotherapy on mortality, change in FVC, or quality
of life, and both interventions (inhaled and oral NAC) have
been given a conditional recommendation against use [23].
However, it has been recently shown that approximately 25%
of patients with IPF (those carrying the TOLLIP rs3750920
TT genotype) may benefit from NAC therapy, whereas those
with the rs3750920 CC genotype may be more susceptible
to treatment-related harm [47]. Future studies are needed
to confirm whether polymorphisms within TOLLIP gene
modify the effect of antioxidant therapy in patients with IPF.
3. Open Questions on the Pharmacologic
Treatment of IPF
3.1. Should We Start Antifibrotic Treatment as Early as
Possible? The US FDA has approved both pirfenidone and
nintedanib with no prescription limitations and regardless of
severity of lung function impairment, although clinical trials
have limited enrollment to patients with mild-to-moderate
IPF. Once the diagnosis of IPF has been established, it con-
ceptually makes sense to start treatment as early as possible
in order to preserve pulmonary function andprolong survival
[48].
In a small minority of patients who are asymptomatic and
have marginal or no lung function impairment, however, it
may not be unreasonable to refrain from starting treatment
and adopt a close clinical/functional surveillance after careful
evaluation of the risks and benefits of such approach and
considering the unpredictable course of IPF.
3.2. Which Drug Should We Use as First-Line Treatment for
IPF? Both pirfenidone and nintedanib have been demon-
strated to slow the decline in FVC in IPF patients with mild-
to-moderate functional impairment with acceptable safety
profiles. However, the data available from clinical trials along
with the lack of head-to-head comparison between the two
drugs do not allow establishingwhether one antifibrotic agent
is superior over the other and should therefore be used first.
Themajor problem of any head-to-head comparison between
pirfenidone and nintedanib is related to the characteristics of
the cohorts investigated in the trials. In fact, the inclusion and
exclusion criteria of ASCEND, CAPACITY, and INPULSIS
trials were different in several ways and resulted in slightly
different study populations being enrolled [18, 19, 27]. It is
therefore difficult, if at all possible, to compare the different
trials to determine better efficacy of these drugs. Moreover,
the new guideline did not consider additional evidence of
efficacy (e.g., improved survival and reduced risk of acute
exacerbations with pirfenidone and nintedanib, resp.) when
formulating their recommendations [23]. This was mainly
due tomethodological issues such as heterogeneity in report-
ing the study results and statistical power of the single study.
The decision as to which agent to use as first-line treatment
should therefore be based not only on drug efficacy but also
on safety profile as well as patient preference, medical history,
concomitant medication, and lifestyle.
3.3. How Do We Treat More Severe IPF? The complexity of
the diagnostic process in IPFmakesmisdiagnosis anddelayed
diagnosis common [49]. Therefore, it is not infrequent in
clinical practice that IPF patients present with advanced
disease and severe functional impairment (percentage of the
predicted FVC < 50%). While no definitive staging system
exists for assessing the severity of the disease, most clinical
trials performed to date, including those of pirfenidone
and nintedanib, have limited their enrolment to patients
with mild-to-moderate functional impairment (FVC ≥ 50%
predicted, DLCO ≥ 30–35%). The assumptions behind such
restricted inclusion criteria are that patients with advanced
disease are less likely to respond to treatment (also because of
the frequent coexistence of severe PH in this setting) andmay
have different and unpredictable response rates andmore fre-
quent and severe adverse events, although there are no con-
vincing data in this regard [50]. Therefore, although the FDA
has approved both pirfenidone and nintedanib regardless of
disease severity (and nintedanib has also been approved by
the European Medicines Agency with the same indication),
we do not know whether pirfenidone and nintedanib are safe
and efficacious also in patients with a more severe functional
impairment (e.g., FVC < 50%) as they have never been
tested in this patient subset. For patients with DLCO < 35%
predicted, echocardiographic evidence of right ventricular
dysfunction, and no contraindications to the drug, a trial of
sildenafil may be a reasonable therapeutic option.
3.4. How Do We Treat Patients with IPF and Lung Cancer?
Patients with IPF are at increased risk of developing lung
cancer.The exact prevalence of this complication is unknown
but is likely to range between 5% and 17% [51, 52]. Risk
factors for lung cancer in IPF include increasing age, male
gender, and greater smoking history [53]. Squamous cell
carcinoma is the predominant cell type of cancer and tends to
localize at the lung periphery and bases (in striking contrast
to what is seen in non-IPF patients) and in close proximity
to the fibrosis, which may potentially be relevant to the
pathogenesis of the neoplastic lesion [54].While themajority
of IPF patients die from progressive disease and respiratory
failure, lung cancer has been reported to account for as
many as 10% of deaths [55]. In addition, recent data show
that the development of this complication has significant
prognostic implications [56, 57]. Whether (and eventually
how) the therapeutic approach should change in patients
with IPF and lung cancer is controversial, and the guidelines
make no specific recommendation in this regard [1]. Our
approach is to make decisions on a case-by-case basis after
careful evaluation of benefits and risks. Indeed, while IPF is
not an absolute contraindication for lung cancer treatment,
acute disease worsening has been reported following tumor
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resection, radiation therapy, radiofrequency ablation, and
chemotherapy [56, 58]. Furthermore, chemotherapy-related
adverse events may potentially affect the patient’s ability to
tolerate antifibrotic therapy.
3.5. How Do We Treat Elderly Patients? While there is no
general agreement on the age at which a person becomes
“old,” in most developed countries persons achieving age
65 years or older are generally defined as elderly. IPF is
strongly associated with advanced age and is highly prevalent
in the elderly [3, 4]. The prognosis of IPF is also significantly
worse in elderly patients than in younger patients [14].
Likely contributors to such adverse outcome include a more
aggressive disease course, lead-time bias with or without
delayed diagnosis, and comorbidities/complications that tend
to be more prevalent and severe in this age group (e.g., coro-
nary artery disease, sleep-disordered breathing, anxiety and
depression, deconditioning, osteoporosis, and diabetes) [58,
59]. Moreover, interpretation of lung function testing (par-
ticularly 6MWT) in this age group may be challenging and
should always be placed in the context of concomitant con-
ditions. For instance, in elderly patients with walk-limiting
musculoskeletal disease or significant frailty with sarcopenia,
6MWTmay not be as useful as in younger patients [59–61].
Pirfenidone and nintedanib are generally safe and well
tolerated, but significant side effects can also occur [18, 19].
Precautions should therefore be used, particularly in elderly
patients taking other medications that may inhibit or induce
the hepatic enzyme systems (e.g., CYP1A2, CYP3A4, and P-
glycoprotein) that metabolize these two drugs. While in the
INPULSIS trials there was no upper age limit for inclusion
in the study [19], in both the CAPACITY and ASCEND
trials patients older than 80 years of age were not enrolled
[18, 27]. However, a post hoc analysis of pooled data from
the CAPACITY and ASCEND trials showed that pirfenidone
had similar efficacy and safety across different age subgroups
(e.g., <65, 65 to 74, or ≥74 years) [62]. Management of elderly
patients with IPF should be as personalized as possible in
order to prevent functional decline and disease progression
but also limit the risk of treatment-related adverse events [59].
4. Future Perspectives
Having two drugs available will lead many physicians to
consider combination therapy, an approach that has been
successfully applied to various respiratory diseases such
asthma, chronic obstructive pulmonary disease, PAH, and
lung cancer. Indeed, owing to the multifactorial and hetero-
geneous nature of IPF and the need to target simultaneously a
multitude of overlapping profibrotic pathways, combination
therapy might be a possibility. The add-on approach is more
likely to be successful if drugs with established efficacy are
used in combination, although a reasonable alternative could
be the addition of a compound sufficiently promising to be
evaluated clinically to a drugwith established efficacy as back-
ground therapy (e.g., pirfenidone or nintedanib) [63]. While
combining two drugs may produce a beneficial synergistic or
additive effect, a weaker effect than expected (either because
themechanism of efficacy, whatever it might be, is targeted by
both drugs and a “ceiling effect” is achieved, or because there
is a blocking interaction) or an unpredictable interaction
that drives disease progression or produces unacceptable side
effects cannot be excluded. Therefore, combination therapy
should be avoided until data are available demonstrating
its efficacy and tolerability/safety in patients with IPF [50].
Recently, a randomized, double-blind, placebo-controlled
phase II, dose escalation trial has been conducted to assess the
safety, tolerability, and pharmacokinetics of nintedanib, alone
and when added to ongoing pirfenidone therapy in Japanese
patients with IPF [64]. Investigators observed a trend toward
lower exposure of nintedanib when added to pirfenidone
and suggested that further study is needed to evaluate the
safety and tolerability profile of pirfenidone and nintedanib
combination in patients with IPF [64].
The notion of “personalized” or “precision” medicine is
based on the potential of customizing healthcare (e.g., deter-
mining disease susceptibility, delivering timely prevention,
predicting outcome, and tailoring the right treatment for the
right patient at the right time) by using molecular profiling
technologies [65]. This approach has been successfully used
to guide treatment decisions in patients with lung cancer
(e.g., carriers of mutations within EGFR, ALK, and K-RAS
genes have the best chance of responding to dedicated tar-
geted therapies). In IPF, like in other complex multipathway
diseases, developments in personalized care could potentially
allow the identification of patient subgroups selectively (or
more) responsive to treatment [66]. However, because of the
multitude of signaling pathways involved simultaneously in
the fibrotic process of IPF, targeted therapies are unlikely to
be truly effective in isolation. Moreover, while personalized
medicine relies on specificity of effect, both pirfenidone and
nintedanib have multiple targets/effects [63]. Combination
therapy and personalized medicine are, in principle, not
mutually exclusive.
Another unsolved issue relates to the management of
patients with possible or probable IPF. In fact, in clinical
practice, a significant minority of patients (e.g., mainly those
unable or unwilling to undergo surgical lung biopsy) cannot
be diagnosed according to current guidelines [1]. Recent data
suggest that a confident diagnosis can be reached in such
patients providing clinical and radiological data are discussed
and interpreted by an experienced multidisciplinary team
[67–71]. Until this diagnostic approach is validated prospec-
tively, we recommend patients with possible or probable IPF
be referred to expert centers for further management.
5. Conclusions
IPF is a progressive and almost invariably deadly disease.
Over the last decade, our understanding of the mechanisms
involved in disease pathobiology has substantially improved.
Similarly, disease definition and diagnostic criteria have
been refined and this had allowed a number of high-quality
clinical trials to be undertaken and completed. This massive
effort of the medical and pharmaceutical community has
led to the approval of two drugs for IPF, pirfenidone and
nintedanib, which means that we may finally have choices for
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the pharmacological treatment of our patients with IPF. Yet,
there is a long way still to go. Indeed, despite significant effect
of antifibrotic therapy on functional decline, a cure for IPF
has yet to be discovered. These limitations notwithstanding,
there is genuine optimism that the concerted effort by the
scientific, professional, and patient community as well as the
pharmaceutical industry will lead soon to the development of
a real cure for patients suffering from this devastating disease.
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